Immunovia's new blood-based testing platform accurately detects non-small cell lung cancer

Immunovia AB announced today that in a new collaborative study with a major global pharma company, Immunovia ́s innovative blood-based testing platform, IMMray^™ could differentiate healthy controls from non-small cell lung cancer (NSCLC) samples with a 95 % accuracy. Accounting for nearly 14% of all new cancers, NSCLC is one of the top three cancer types by incidence and number one by mortality.

The study included 100 serum samples - 50 NSCLC and 50 controls - and was performed to assess the technical performance of the IMMray^™ platform in lung cancer. As a consequence of the encouraging high diagnostic accuracy of 95% obtained with IMMray™ during this project, the parties now plan for continued collaboration by adding larger studies to confirm these preliminary findings.

“Since IMMray^™ has previously demonstrated similar high (98%) accuracy in detecting pancreatic cancer, the results from this study strengthen our belief that IMMray^™ has the potential to become a standard common platform for cancer diagnosis based on blood samples, and we are very much looking forward to the next steps of this collaboration”, CEO Mats Grahn said in a statement.